Javier Martínez-Picado

Institut de Recerca de la Sida - IrsiCaixa

Life & Medical Sciences

Javier Martínez-Picado is ICREA Research Professor at the AIDS Research Institute irsiCaixa in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the University of Vic (UVic-UCC). He received his PhD from the University of Barcelona where he subsequently became associate professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of the Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hospital "Germans Trias i Pujol" in Badalona (Barcelona). Dr. Martínez-Picado serves on different government, academic and industry advisory boards and has published extensively on HIV treatment strategies and HIV pathogenesis in international journals.

Research interests

The main subject of our biomedical research is the Human Immunodeficiency Virus (HIV), a retrovirus that can lead to Acquired ImmunoDeficiency Syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. Since the beginning of the epidemic, 76 million people have been infected with HIV, of which 35 million have died from AIDS. In 2016, 1 million people died from AIDS-related causes and 1.8 million became newly infected worldwide.

Our research programs are focused on understanding how HIV causes disease at the molecular and cellular level, tackling cellular and anatomical viral reservoirs, exploring new strategies to cure HIV/AIDS and collaborating on global HIV/AIDS vaccine development projects.

Selected publications

- Martinez-Picado J et al 2017, ‘Retroviruses as myeloid cell riders; what natural human Siglec-1 “knockouts” tell us about pathogenesis’, Front Immunol, Nov 2017(8):1593.

- Morón-López S et al. 2017, ‘Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue’, PLoS One 12(4):e0175899.

- Martínez-Bonet M et al 2017, 'Relationship between CCR5(Δ32/WT) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection', Clin Microbiol Infec, 23(5):318-24.

- Minuesa G et al 2017, ‘Response to: Tenofovir disoproxil fumarate is not an inhibitor of human organic cation transporter 1’. J Pharmacol Exp Ther 360:343-5.

- Hancock G et al 2017, ‘Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in ART-treated subjects’, J Int AIDS Soc 20(1):21171.

- Codoñer FM et al 2017, ‘Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to protease inhibitor’, Sci Rep-UK 7(1):3717.

- Rosas-Umbert M et al 2017, 'Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B', Plos One, 12(9):e0184929.

- Ruiz-Riol M et al 2017, 'Identification of IL-27/IL-27RA as a critical immune axis for in vivo HIV control', J Virol 91(16):e00441-17

- Molinos-Albert LM et al 2017, 'Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif', Sci Rep-UK, 7:40800.

- Baptista MJ et al 2017, 'Epstein-Barr viral loads and serum free light chains levels are potential
follow up markers of HIV-related lymphomas', Leukemia Lymphoma, 58(1):211-213.